Microbot Medical Inc. has announced a significant advancement in its global intellectual property strategy with the granting of a new patent in China by the China National Intellectual Property Administration (CNIPA). This patent covers the robotic manipulation of a surgical tool handle, further bolstering the company's IP portfolio. This development is a key component of Microbot Medical's plan to expand its global commercialization strategy for its LIBERTY Endovascular Robotic System, which is pending FDA clearance and anticipated for a Q3 2025 launch in the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.